NanoViricides, Inc. (NYSE American: NNVC), a clinical-stage antiviral drug developer, has reported progress in its Phase IIA clinical trial of NV-387 Oral Gummies for the treatment of Ebola Bundibugyo virus infection in the Democratic Republic of Congo. The exploratory trial, which will enroll up to 20 patients with varying disease severity, is evaluating the safety and tolerability of treatment regimens lasting six to 12 days. While the study is not designed to establish statistically significant efficacy, it may identify preliminary signs of antiviral activity, according to the company. Following completion and evaluation, NanoViricides plans to advance an appropriate dosing regimen into an expanded, randomized, controlled Phase IIB study, provided the findings support further development.
The implications of this announcement extend beyond a single drug candidate. Ebola outbreaks, particularly in regions with limited healthcare infrastructure, remain a significant global health threat. Current treatments often require intravenous administration and cold-chain logistics, which can be challenging in outbreak settings. NV-387 is an oral gummy formulation, a delivery method that could simplify deployment and improve patient compliance. If successful, it would offer a practical option for managing Ebola and potentially other viral diseases.
NV-387 is a broad-spectrum antiviral candidate designed to reduce viral load by targeting host-cell features used by viruses during infection. Unlike traditional antivirals that target specific viral proteins, this host-directed approach may be less susceptible to viral resistance and could be effective against a range of viruses. The company is also developing NV-387 for respiratory viral infections such as RSV, COVID, and influenza, as well as for MPOX/Smallpox and measles. This versatility positions NV-387 as a potential platform therapeutic, which could be rapidly adapted to emerging viral threats.
The trial's progress is noteworthy because it represents one of the few clinical-stage efforts to develop an oral treatment for Ebola. The Democratic Republic of Congo has experienced multiple Ebola outbreaks, including the Bundibugyo strain, which has no approved vaccines or therapeutics. If NV-387 demonstrates safety and preliminary efficacy, it could fill a critical gap in outbreak response strategies. Moreover, the Phase IIB study, if initiated, would provide more robust data on efficacy and dosing, potentially paving the way for regulatory approval.
Investors and industry observers will be watching closely. NanoViricides' lead drug candidate, NV-387, is also being developed for other high-impact viruses, and positive results in Ebola could accelerate development across its pipeline. The company's focus on broad-spectrum antivirals aligns with global preparedness efforts for pandemic threats. For more details, the full press release is available at https://nnw.fm/9fDB5. Additional information about the company can be found at www.nanoviricides.com, and the latest updates are available in its newsroom at https://nnw.fm/NNVC.
The announcement was distributed through NetworkNewsWire, a specialized communications platform that is part of the Dynamic Brand Portfolio at IBN. The platform provides services including InvestorWire for wire distribution, editorial syndication to 5,000+ outlets, press release enhancement, and social media distribution to millions of followers. For full disclaimers, visit https://www.NetworkNewsWire.com/Disclaimer.


